Amphastar Pharmaceuticals, INC Form 4 insider transactions

Jack Y. Zhang, CEO, and Mary Z. Luo, COO, of Amphastar Pharmaceuticals, reported disposing of shares to cover tax liabilities related to vesting restricted stock units.

Amphastar Pharmaceuticals' CEO Jack Y. Zhang and COO Mary Z. Luo receive stock options and restricted stock units (RSUs) vesting annually starting March 4, 2025.

Director Michael Zasloff of Amphastar Pharmaceuticals sold a total of 12,500 shares of common stock on March 5, 2024, in two separate transactions.

Yakob Liawatidewi, EVP Corp Admin Center at Amphastar Pharmaceuticals, reports acquisition of shares and stock options.

Senior EVP Rong Zhou reports acquisition of stock options and restricted stock units in Amphastar Pharmaceuticals.

William J. Peters, CFO, EVP & Treasurer of Amphastar Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Floyd F. Petersen, a director at Amphastar Pharmaceuticals, sold a portion of his holdings under a pre-arranged Rule 10b5-1 trading plan.